Recruiting NCT07717918
A Study of BL1332 on Capsaicin-Induced Ocular Pain in Healthy Trial Participants
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: BL1332 eye drops, BL1332 Placebo eye drops.
- Who it may be relevant to
- Registry conditions: Healthy. Basic parameters: 18 years — 65 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
A Phase 1B Study of BL1332 on Capsaicin-Induced Ocular Pain in Healthy Subjects
Overview
Single center, double-masked study of BL1332 on Capsaicin-Induced Ocular Pain in Healthy Subjects
Interventions
- Drug BL1332 eye drops
Taken 1 time - Drug BL1332 Placebo eye drops
Taken 1 time
Primary outcome measures
- Ocular pain severity assessed by numeric pain rating scale (NPRS) [Time frame: Assessed 5 seconds post-capsaicin dose]
Eligibility criteria
Inclusion criteria
- Male or female ≥ 18 to ≤ 65 years of age.
- In good health, as assessed at Screening by the Investigator from past medical history, physical examination (abbreviated), and laboratory tests.
- Does not wear contact lenses, or is willing to refrain from wearing contact lenses for the duration of the study.
Exclusion criteria
- Women of childbearing potential or non-vasectomized males with partners of childbearing potential are not eligible unless they are using an effective method of contraception and agree to use an effective method of contraception until at least 30 days after study treatment.
- Any medical condition (systemic or ophthalmic) that may, in the opinion of the Investigator, preclude the safe administration of IP, safe participation in this study, or confound the assessment of safety or efficacy.
- Unwilling or unable to comply with the study protocol.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Double blind
- Primary purpose
- Treatment
Study locations
United States · 1 center
- Site 101 — Newport Beach
Identifiers
NCT: NCT07717918 · BL-RX01-BL1332-1102